A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function

NCT05015894 | Completed Phase 1

• 3 other identifiers: NN9389-46822021-001450-57U1111-1266-0594
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Novo Nordisk is developing a combination therapy with the study medicine NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D). It is expected that the combination will further improve the blood sugar control compared to semaglutide therapy alone.In this study the blood levels of NNC0480-0389 will be compared in people with various degrees of reduced kidney function to the blood levels in people with normal kidney function, after administration of one dose of 18 mg NNC0480-0389. Participants will only get the study medicine as two injections into a skinfold of participants belly (subcutaneous). The study will last for about 65 days including a screening phase of up to 28 days prior to dosing. If participants are eligible for the study, participants will have 11 visits to the study centre including one in-house stay of 5 days and 4 nights (Visit 2) and nine ambulatory visits (Visit 3 to Visit 11). Participants' vital signs (heart rate, blood pressure, body temperature) will be measured, participants will have blood drawn, urine will be collected and electrocardiograms (ECGs) will be recorded.If participants are women and can get pregnant they cannot take part in the study. A hormone test will be done to check if participants may be post-menopausal.

Conditions

Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

• AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose

  h\*nmol/L

  From baseline (visit 2, day 1, pre-dose) until completion of the end-of-study visit (visit 11, day 36)

Secondary Outcomes (1)

• Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose

  From baseline (visit 2, day 1, pre-dose) until completion of the end-of-study visit (visit 11, day 36)

Study Arms (1)

NNC0480-0389

EXPERIMENTAL

All participants will be administered a single s.c. dose of 18 mg NNC0480-0389

Drug: NNC0480-0389

Interventions

NNC0480-0389 DRUG

A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin). Total duration of study participation for each participant is 38 to 66 days

NNC0480-0389

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female of non-childbearing potential, aged 18-75 years (both inclusive) at the time of signing informed consent.
• Body mass index (BMI) between 20.0 and 39.9 kg/m\^2 (both inclusive)
• Meeting the pre-defined GFR criteria using estimated GFR (eGFR) based on serum creatinine for any of the renal function groups:
• For participants with normal renal function: eGFR of equal to or greater than 90 mL/min
• For participants with mild renal impairment: eGFR of 60-89 mL/min
• For participants with moderate renal impairment: eGFR of 30-59 mL/min
• For participants with severe renal impairment: eGFR of 15-29 mL/min not requiring dialysis
• For participants with kidney failure: eGFR of less than 15 mL/min or requiring dialysis treatment
• \* Current treatment with haemodialysis

You may not qualify if:

• Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• Use of prescription medicinal products or non-prescription drugs, or non-routine vitamins, which at the investigators judgement may affect participant safety or the results of the study within 14 days before screening.
• Use of drugs known to affect creatinine clearance including cephalosporin and aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim and cibenzoline within 14 days or 5 half-lives, whichever is greater, before dosing the investigational medicinal product (IMP).
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions (except conditions associated with renal impairment or kidney failure).

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk Investigational Site

Berlin, 10117, Germany

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Clinical Transparency (Dept. 1452)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2021
• First Posted: August 23, 2021
• Study Start: August 30, 2021
• Primary Completion: August 2, 2022
• Study Completion: August 2, 2022
• Last Updated: November 13, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)